EF Hutton analyst Michael Albanese reiterates Glimpse Group (NASDAQ:VRAR) with a Buy and maintains $7 price target.
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks’ Cells
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against Ultragenyx's motion to dismiss, allowing the case to continue.
